Skip to content
Therapy But Better – Lifestyle
Author:
Immix Biopharma, Inc.
Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock
September 30, 2026
Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis
September 29, 2026
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
September 29, 2026
Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
August 4, 2026
Immix Biopharma Announces Closing of $150 Million Underwritten Offering of Common Stock
May 22, 2026
Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock
May 21, 2026
Immix Biopharma Announces 95% Complete Response Rate in Interim Update From relapsed/refractory AL Amyloidosis Clinical Trial NEXICART-2
May 21, 2026
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
April 9, 2026